№ lp_1_2_65470
File format: docx Character count: 23409 File size: 509 KB
This guideline provides recommendations for the safe prescribing of gabapentinoids (gabapentin and pregabalin) for chronic pain management in primary care settings in Scotland, focusing on person-centered care and considering non-pharmaceutical management options.
Year: 2018
Region / City: Scotland
Topic: Chronic pain management, gabapentinoids prescribing
Document type: Guideline
Organization / Institution: Scottish Government
Author: Heather Harrison, Jason Cormack
Target audience: Clinicians, healthcare professionals, Boards
Period of validity: Ongoing
Approval date: 11th December 2018
Date of revisions: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Gabapentinoid suggested tapering regimes for gabapentin and pregabalin in adults with persistent pain
Year: 2021
Language: English
Medical field: Pain management
Therapeutic class: Gabapentinoids
Medications covered: Gabapentin; Pregabalin
Indications discussed: Neuropathic pain
Patient population: Adults with persistent pain
Document type: Clinical guidance
Related guidance: Analgesic Tapering Guidelines for adult patients with persistent pain taking strong opioids and/or gabapentinoids
Regulatory references: NICE; MHRA
Dosage information: Included
Tapering schedules: Included
Risk considerations: Adverse effects; withdrawal effects; opioid co-prescribing risks
Geographic context: United Kingdom
Evidence sources: Cochrane Reviews; NICE guidance; Summary of Product Characteristics
NHS Shropshire, Telford and Wrekin Guidance: Gabapentinoid Prescribing in Chronic Pain
Year: 2018–2021
Region: Shropshire, Telford and Wrekin
Subject: Gabapentinoid prescribing in chronic pain
Document Type: Clinical prescribing guidance
Issuing Body: NHS Shropshire, Telford and Wrekin
Medicines Covered: Gabapentin; Pregabalin
Legal Framework: Misuse of Drugs Regulations 2001; Misuse of Drugs Act 1971
Clinical Scope: Chronic pain management
Key Topics: Misuse potential; Co-prescribing with opioids; Legal status; Off-label use; Risk management; Dose reduction; Cross-tapering; Renal function
Intended Audience: Prescribers and healthcare professionals
Appendices: Prescribing agreement; Example dose reduction; Example cross-taper; Direct switch guidance
Status: Schedule 3 Controlled Drugs (from 1 April 2019)
Topics: CareResources BoardsVERSION Gabapentinoid